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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not “Does
Buzzy® reduce needlestick pain in children between the ages 5 and 12 years old?”
STUDY DESIGN: A systematic review of three nonblinded, randomized controlled trials
(RCTs). All studies were published in English between 2018 and 2019.
DATA SOURCES: Three RCTs were obtained from PubMed and published in peer-reviewed
journals. The studies were chosen based on their relevance to the clinical question.
OUTCOMES MEASURED: In all of the articles used for this review, the main outcome
measured was pain reduction. The participants’ level of pain was measured with either the Faces
Pain Scale-Revised (FPS-R) or the Oucher Scale. Self-reported pain levels were assessed either
immediately after the procedure was completed, one minute after the procedure was completed,
or during the procedure.
RESULTS: In the RCT conducted by Bilgen et al., there was a significant reduction in pain with
the use of Buzzy® compared to the control group. The mean pain difference between the control
group and Buzzy® group was 3.72. The p-value was calculated to be <0.001, making this study
statistically significant with a large treatment effect. The RCT conducted by Sahiner et al.
showed a mean pain difference between the control group and Buzzy® group of 1.94, with a
calculated p-value of 0.008. This study was shown to be statistically significant and had a large
treatment effect. In the RCT conducted by Alemdar et al., the mean pain difference was 2.36
with a p-value of 0.001. The study was found to have a large treatment effect and statistically
significant.
CONCLUSIONS: Statistical significance was found in all RCTs based on the calculated pvalues. The Buzzy® intervention group in each study showed a large treatment effect when
comparing pain levels to the control group. The results of this review are conclusive and show
that the use of Buzzy® to reduce needlestick pain in children is effective. Future studies could be
conducted with blind raters.
KEYWORDS: Buzzy®, needlestick, pain, children
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INTRODUCTION
Needles are used to accomplish a variety of medical procedures in both children and
adults every day in outpatient and inpatient settings. There is a broad spectrum for the use of
needles in the healthcare field, including medication administration, venous access, and more.
More specifically, certain antibiotics such as penicillin G or ceftriaxone, are given to patients via
intramuscular injections using a needle. When a patient requires continuous administration of
fluids or administration of a medication directly into the venous blood stream, an intravenous
(IV) catheter will be placed in the arm or hand of the patient using a needle to penetrate the skin
and vein. Phlebotomy is another common medical procedure, and it is performed when a needle
is used to access a vein one time to draw blood for laboratory tests.
Vaccines are a common practice in the United States and are administered to children and
adults via a needle as well. The number of injections for children have increased from six to
thirty total injections as the vaccine recommendations have changed over the years.1 In the
United States specifically, the recommend vaccines for all children between the ages 5 and 12
years old includes DTaP, IPV, MMR, varicella, influenza, HPV, and meningococcal disease
vaccines, all requiring the use of a needle.2
Other necessary medical procedures that involve a needlestick are subcutaneous insulin
injections. Children diagnosed with type 1 diabetes mellitus require daily insulin injections with
a needle to manage their blood glucose levels appropriately. According to the Juvenile Diabetes
Research Foundation (JDRF), there are about 200,000 people under the age of 20 years old who
live with type 1 diabetes mellitus and require insulin injections in the United States.5 These
patients must endure multiple painful injections throughout the day, every day, and at multiple
sites on the body.

Gilcrest÷ Buzzy® and Pain Reduction

2

While a needlestick can be painful for a patient of any age, children are more susceptible
to experiencing clinically significant pain than adults.6 With children, the response to pain is
determined by genetic factors, prior experiences, and developmental factors.6 When a child
endures a painful medical procedure such as needlesticks, negative repercussions may occur
including the development of needle phobia.6 The child may become scared of needles and
healthcare professionals, and they can become reluctant to cooperate during such interventions.6
If a child experiences a painful medical procedure with a needle, they may feel more anxious and
tense in subsequent situations which can lead to heightened pain.6 In children, the fear of needles
has grown from 25% in 1995 to 63% in 2012.1 The provider administering the vaccine may end
up spending more time trying to console the child and get them to cooperate for the procedure.
This fear and reluctance can interfere with the child receiving proper treatment for an illness or
interfere with compliance to immunization schedules.
A standard needlestick procedure most commonly involves informing the patient about
the procedure prior to beginning, cleaning the intended injection area, and using the proper
injection technique for the type of injection being performed. A bandage can be applied over the
injection site after the procedure is done. Distraction is often used in attempt to reduce
needlestick pain in children by offering the patient positive reinforcement, a toy, or a sticker as a
reward.
The Buzzy® device is applied to a child’s skin to decrease the pain that is felt when a
needlestick procedure is being performed, such as vaccinations, IM injections, and subcutaneous
injections. The device works by utilizing the gate control theory of pain, which involves the
stimulation of different types of nerve fibers in the body.8 Nerve fibers that send pain signals to
the brain are called A-delta and C fibers.8,9 In contrast, the nerve fibers that send non-painful
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signals to the brain, such as vibration and touch, are called A-beta fibers.8,9 The vibration from
Buzzy® works to block the pain signals to the brain that come from A-delta and C fibers by
stimulating the A-beta nerve fibers and activating an inhibitory response.8,9 In addition to the
vibration, Buzzy® has an attachable cold pack that works to reduce pain during a needlestick
procedure by using descending inhibitory pain modulation.7-9 When the cold pack is applied to
the skin, C fibers are activated and block the A-delta fibers that recognize pain.8,9 By stimulating
the C fibers with the cold pack, a slower pain and thermal signal is sent to the brain, activating a
supraspinal modulation which leads to an increase in the body’s pain threshold.7-9 This paper
evaluates three randomized controlled trials that study the use of Buzzy® to reduce needlestick
pain in children compared to the pain experienced with standard needlestick care without a pain
reducing intervention.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not “Does Buzzy®
reduce needlestick pain in children between the ages 5 and 12 years old?”
METHODS
The criteria that were used to select the three randomized controlled trials discussed in
this systematic review included the investigation of the use of Buzzy® and its effectiveness in
reducing needlestick pain in children. The studies that were chosen were found on PubMed and
all of the articles were published in peer-reviewed journals using the English language. The three
RCTs look at the use of the device, Buzzy®, compared to standard needlestick care and
measured the outcome of pain intensity either during or after the needlestick procedure. The
population being studied in this systematic review includes children between the ages 5 and 12
years old.
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The keywords used to select relevant articles were “Buzzy” and “pain.” The studies were
chosen based off of the age group that was studied in each article, the patient-oriented outcome
measured, and their clinical relevance to the review’s question, “Does Buzzy® reduce
needlestick pain in children between the ages 5 and 12 years old?” The inclusion criteria for the
selection of studies were randomized controlled trials and children as the population being
studied. Exclusion criteria included secondary studies, primary studies that were not RCTs,
studies whose population was not children, and studies dated prior to 2015. The statistics
reported in the articles for measuring the outcome of pain intensity were p-values, mean,
standard deviation, and median. Table 1 shown below contains the demographics in the studies.
OUTCOMES MEASURED
The major outcome measured in the RCTs was the reduction of pain intensity for children
who underwent a needlestick procedure. Subjective pain intensity was measured using the Faces
Pain Scale-Revised (FPS-R) in the articles conducted by Bilgen et al.10 and Sahiner et al.11 The
FPS-R uses six different facial expressions that are ranked on a scale of zero to ten according to
the level of pain intensity, with zero representing no pain and ten representing the most pain.11
The children using this scale did not need to understand numbers or words, therefore making it
an ideal way to accurately measure their pain.10 In the study conducted by Bilgen et al.,10 the
children were asked to select their pain level based off of the FPS-R after the 1st minute
following the needlestick. In the study conducted by Sahiner et al.,11 the FPS-R was given to the
children to assess their pain level immediately after the needlestick.
The study conducted by Alemdar et al.12 measured the pain intensity of the participants
using the Oucher Scale. This scale has two parts; one part consists of six pictures of children
with different facial expressions based on their pain level, and the other part is a numerical scale
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with the numbers 1 through 10 on it.12 The children who were able to determine which number
on the scale was larger were able to point to the number in which they thought coordinated with
their pain levels, and the children who were unable to decipher the larger of two numbers pointed
to the facial expression they believed represented their pain level.12
Table 1. Demographics & Characteristics of Included Studies
#
Age
Inclusion
Study
Type
Exclusion Criteria
Pts (yrs)
Criteria
Alemdar12 RCT 78 5-10 5-10 years old, Use of another local
(2019)
requiring blood anesthetic, signs of skin
tests,
infection at site,
accompanied
significant
by family
trauma/disease needing
member
rapid evaluation,
developmentally
delayed, chronically ill,
altered sensorium,
allergic to lidocaine,
neurosensory deficit

W/D Interventions
0

Buzzy® was
applied to the
injection area

Bilgen10
(2019)

RCT

100 7-12

Children 7-12
years old who
presented to
the Pediatric
Emergency
Clinic,
required IM
injection of
procaine
penicillin

Presence of a disease
that causes chronic pain,
neurodevelopmental
disorders, analgesics use
within the last 6 hrs, hx
of fainting during
injection, learning
disabilities

0

Buzzy® was
applied to the
injection area

Sahiner11
(2018)

RCT

40

Patients
diagnosed with
Type 1
Diabetes
Mellitus,
insulin injected
by the same
nurse, children
cognitively
able to rate
their pain and
anxiety

Patients with
0
pacemakers,
infection/rash/
deteriorated skin
integrity, nerve damage,
critical or unstable health
status, intellectual
disabilities, analgesic use
within 6 hrs of
procedure, Reynaud’s
Syndrome, SCD,
unwilling to participate

Buzzy® was
applied to the
injection area

6-12
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RESULTS
Sahiner et al.11 conducted a randomized controlled trial to evaluate the level of pain
intensity children between the ages 6 and 12 years old experienced with insulin administration.
The population studied included children diagnosed with type 1 diabetes mellitus who required
routine insulin injections at the Child Endocrinology Department in Eskisehir Osmangazi
University.11 This study was conducted between May 2015 and June 2017. The control group
and the Buzzy® intervention group each consisted of 20 children.11 The children were randomly
placed in either group based upon which color ball they blindly and randomly chosen from
within a black bag.11 For the control group, the participants were only informed that they were
about to receive an injection.11 The intervention group used Buzzy® during the administration of
the insulin injection.11 Buzzy® was placed on the surface of the participant’s skin, 5 centimeters
above the injection site, prior to administration.11 The low frequency vibration and the cold pack
were kept on the skin until the administration of insulin was complete.11
The children were asked to record their pain level immediately after the procedure was
completed using the Faces Pain Scale-Revised.11 The scale consisted of six varying facial
expressions alongside a numerical scale between 0 and 10, with 0 representing no pain and 10
representing the most pain.11 The statistical data used to measure the pain intensity in the study
by Sahiner et al.11 was presented as mean values, standard deviation, median, and p-values. The
control group showed a mean self-reported procedural pain score of 3.2 with a standard deviation
of 2.78.11 This was higher than the intervention group that used Buzzy®, which showed a mean
procedural pain score of 1.26 with a standard deviation of 1.36.11 The mean pain difference
between the control group and the Buzzy® group was 1.94, resulting in a large treatment
effect.11 The median pain score for the control group was 4.00 compared to the median pain
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score of the Buzzy® group which was 2.00.11 The calculated p-value for the self-reported
procedural pain scores was 0.008, therefore statistical significance is present in this study.11
Resultant values from this study are shown in Table 2 as seen below.
Table 2. Comparison of Procedural Pain Scores of the Study Groups (data from Sahiner et
al.11)
Mean Difference
Mean (SD)
Median
Between Groups
P-Value
(calculated)
Control
3.2 (2.78)
4.00
Group
1.94
0.008
Buzzy Group 1.26 (1.36)
2.00
Bilgen et al.10 conducted a randomized controlled trial that compared the level of pain
intensity experienced in routine needlestick procedures compared to needlestick procedures
using Buzzy®. The participants included children between the ages 7 and 12 years old who
required an intramuscular (IM) injection of procaine penicillin at the Pediatric Emergency Clinic
in Turkey between September 2014 and February 2015.10 A computer program that randomized
numbers was used to randomly assign participants to the control group or the Buzzy® group.10
The control group and Buzzy® group each consisted of 50 children.10
The Buzzy® device and the attachable cold pack were applied to the skin of the
participants about 3 to 5 centimeters above the injection site.10 The vibration and cold pack were
used for an average of 60 seconds prior to the needlestick and remained in contact with the skin
until after the procedure was completed.10 The children in the control group received a routine
administration of procaine penicillin without any accessory device to modify pain.10
The outcome measured in the study by Bilgen et al.10 was pain intensity. The Faces Pain
Scale-Revised was used to evaluate the level of pain the participants felt after the first minute
following an IM injection.10 The statistical data for this study was presented as mean values,
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standard deviation, and p-values.10 The control group demonstrated a FPS-R mean score of 7.36
with a standard deviation of 3.09 for the evaluation of pain one minute after the injection was
administered.10 In comparison, the Buzzy® group demonstrated a mean pain score of 3.64 with a
standard deviation of 3.10.10 The calculated mean pain level difference between the two groups
was 3.72. The p-value for the pain score one minute following the injection was <0.001, making
the statistic highly significant with a large treatment effect.10 Values for this study can be seen in
Table 3 as seen below.
Table 3. Comparison of the First Minute Faces Pain Scale—Revised (FPS-R) Mean Scores
of the Children according to Groups (data from Bilgen et al.10)
Mean Difference
Mean + SD
Between Groups
P-Value
(calculated)
Control Group

7.36 + 3.09

Buzzy® Group

3.64 + 3.10

3.72

<0.001

Alemdar et al.12 conducted a RCT to evaluate self-reported pain intensity in participants
requiring blood tests and needlestick procedures. The participants were children between the
ages 5 and 10 years old who required phlebotomy procedures in the Phlebotomy Unit of a
Maternity and Children Training and Research Hospital in Turkey.12 This study was conducted at
this location between May 2016 and September 2017. A computer program was used to
randomly assign each child to a specific group.12 The control group included 39 children and
they received no pain relief interventions.12 The intervention group utilized Buzzy® and
contained 39 children as well.12
Venipuncture procedures were done by pediatric nurses on each child and required use of
a Vacutainer® system and 21G butterfly needle.12 The Buzzy® device and its attachable cold
pack were placed on the skin 3 to 5 centimeters above the venipuncture site, held in place for 30
to 60 seconds prior to the needlestick, and continued until the venipuncture was completed.12 The
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children in this study by Alemdar et al.12 were asked to rate their pain using the Oucher Scale
during the phlebotomy procedure.
The statistical data used to measure the level of pain experienced by each group of
children was presented as mean values, standard deviation, and p-values.12 The control group
showed a mean Oucher score of 5.87 with a standard deviation of 2.87 during the venipuncture
procedure.12 The Buzzy® intervention group demonstrated a mean Oucher score of 3.51 with a
standard deviation of 3.49.12 The p-value for Oucher scores during venipuncture was 0.001,
making this data highly significant.12 The mean difference between the control group pain score
and the Buzzy® group pain score is 2.36, demonstrating a large treatment effect. The values for
this study can be seen in Table 4 below.
Table 4. Oucher Score Comparisons Between the Control Group and the Intervention
Group (data from Alemdar et al.12)
Mean Difference
Mean + SD
Between Groups
P-Value
(calculated)
Control Group

5.87 + 2.87

Buzzy® Group

3.51 + 3.49

2.36

0.001

DISCUSSION
Needles are used in a variety of everyday medical procedures such as venipuncture,
antibiotic injections, insulin injections, vaccinations, and more. Many children in the United
States are diagnosed with type 1 diabetes mellitus and require multiple subcutaneous insulin
injections every day to survive. The recommended vaccinations have also increased over the
years, leading to an increased frequency of needlesticks in children.1 The high level of
discomfort felt by patients who receive a needlestick can have negative effects on their future
experiences, especially in children. Children are more susceptible to clinically significant and
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distressing pain.1 If a child has a painful experience with a needlestick procedure, then they may
begin to develop needle phobia and fear the use of needles.1 Healthcare professionals may end up
spending an excessive amount of time consoling a scared child before using a needle.4 If a child
becomes uncooperative, he or she may not receive the best treatment available for their illness or
they might miss a necessary vaccination and delay subsequent vaccinations.1
This systematic review evaluated the efficacy of applying a vibrating device, Buzzy®,
with an attachable cold pack to reduce needlestick pain in children between the ages 5 and 12
years old. All three RCTs were determined statistically significant based off of their p-values.1012

In each study, the pain level was significantly lower in the Buzzy® group than it was in the

control group that did not use a pain modulating intervention.10-12 Sahiner et al.11 demonstrated a
mean pain score difference of 1.94 between the control group and Buzzy® group. In the study
conducted by Bilgen et al.,10 the mean pain score difference was 3.72. This was the largest mean
pain score difference out of the three studies. Alemdar et al.12 demonstrated a mean pain score
difference of 2.36. The treatment effect for all three studies was determined to be large, based
upon the mean difference between control groups and Buzzy® groups.
The studies used in this review consisted of few limitations. In all three studies, all
participants including researchers, children, and nurses were not blinded to the intervention.10-12
By not being able to blind the child to the intervention, this could have induced bias in their pain
scores. The studies also did not utilize blind raters, such as having a designated rater evaluate the
children of the studies with the FPS-R or Oucher scale without seeing the intervention being
utilized. Another limitation across all three studies includes the difference between each
participants’ cultural, physical, and emotional states.12 These differences could have influenced
the pain scores.12 In the RCT conducted by Bilgen et al.,10 there was one additional limitation
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discussed. This study used a single researcher who stayed with every participant during the IM
injections and also assessed the pain scores reported by the participants. Bias may have been
induced by having the same person administer the intervention and evaluate the results of the
self-reported pain scores.10 In the RCT conducted by Sahiner et al.,11 some of the participants
may have had lipodystrophy prior to the study being conducted due to their daily administration
of insulin. A child with lipodystrophy could have a heightened or altered pain response with the
subcutaneous injections being performed.11
CONCLUSION
All three randomized controlled trials that were utilized to conduct this systematic review
demonstrated that the use of Buzzy® effectively reduced the pain felt by children between the
ages 5 and 12 years old who underwent some type of needlestick procedure. The treatment effect
in each study was determined to be large based upon the mean pain score difference between
control groups and Buzzy® intervention groups. Thus, the results of this review are conclusive
and found statistically significant based off of the calculated p-values.
Future studies investigating the use of Buzzy® to reduce needlestick pain in children
should use a larger quantity of patients in each group. The future studies should also take into
consideration different cultural, emotional, and physical states of the participants and how these
differences can affect self-reported pain levels. It may be beneficial to have blind raters to assess
the children’s pain scale using the FPS-R or Oucher scale without seeing the intervention being
used.
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